AM vs AR

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong profitability metrics like an 81.29% gross margin and 22.52% ROE, the company faces significant risks including a high 91.84% dividend payout ratio, elevated debt/equity of 1.46, and deteriorating earnings momentum. Insider selling, weak recent earnings beats (1 of last 4), and a technical trend score of 10/100 further signal caution. Although the stock trades near analyst target ($18.75 vs $18.93), it is overvalued relative to the Graham Number of $9.77, suggesting limited margin of safety for defensive investors.

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline stable health, while the absence of an Altman Z-Score prevents a clear distress risk assessment. The stock trades above the Graham Number ($31.83) at $34.29, suggesting a slight premium, though below the analyst target of $43.30. Solid revenue growth (13.4% YoY) and strong gross margins (67.0%) are offset by weak earnings consistency, deteriorating recent EPS trends, and poor liquidity metrics. Analysts recommend a 'buy', but insider sentiment is neutral with no recent transactions.